[{"indications": "Indications\u00a0treatment of osteoporosis in postmenopausal women\r\nat high risk of fractures (to reduce the risk of vertebral fractures)\r\n(see also notes above)", "name": "PARATHYROID HORMONE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.6 Drugs affecting bone metabolism", "6.6.1 Calcitonin and parathyroid hormone", "PARATHYROID HORMONE"], "cautions": "Cautions\u00a0monitor serum or urinary calcium concentration\r\nat 1, 3 and 6 months after initiation of treatment (consult product literature for guidance if serum-calcium concentration\r\nraised); active or previous urolithiasis; concomitant cardiac glycosides", "side-effects": "Side-effects\u00a0nausea, vomiting, dyspepsia, constipation, diarrhoea;\r\npalpitation; headache, dizziness, fatigue, asthenia; transient hypercalcaemia,\r\nhypercalciuria; muscle cramp, pain in extremities, back pain; injection-site\r\nreactions; less commonly abdominal pain, altered\r\nsense of smell, taste disturbance, anorexia, influenza, hyperuricaemia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/129906.htm", "doses": ["By subcutaneous injection, 100\u00a0micrograms\r\ndaily, max. duration of treatment 24 months"], "pregnancy": "Pregnancy\u00a0avoid"}]